Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,603 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,603 shares of the stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total transaction of $301,283.85. Following the completion of the sale, the chief executive officer directly owned 155,855 shares in the company, valued at $29,292,947.25. This trade represents a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, October 1st, Steven Leonard Chapman sold 14,083 shares of Natera stock. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00.
• On Tuesday, September 30th, Steven Leonard Chapman sold 9,109 shares of Natera stock. The stock was sold at an average price of $162.05, for a total transaction of $1,476,113.45.
• On Tuesday, September 2nd, Steven Leonard Chapman sold 5,079 shares of Natera stock. The stock was sold at an average price of $166.53, for a total transaction of $845,805.87.
• On Friday, August 1st, Steven Leonard Chapman sold 5,807 shares of Natera stock. The stock was sold at an average price of $132.88, for a total transaction of $771,634.16.
• On Monday, July 28th, Steven Leonard Chapman sold 6,092 shares of Natera stock. The stock was sold at an average price of $139.81, for a total transaction of $851,722.52.

Natera Price Performance

Shares of NTRA stock opened at $188.02 on Thursday. The company has a market capitalization of $25.81 billion, a P/E ratio of -98.44 and a beta of 1.74. The company’s 50-day simple moving average is $169.97 and its two-hundred day simple moving average is $159.37. Natera, Inc. has a one year low of $117.27 and a one year high of $196.63.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera’s revenue was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Several institutional investors have recently bought and sold shares of NTRA. Guided Capital Wealth Management LLC lifted its stake in shares of Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after buying an additional 66 shares during the period. Main Management ETF Advisors LLC lifted its stake in shares of Natera by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock worth $743,000 after buying an additional 72 shares during the period. Yousif Capital Management LLC lifted its stake in shares of Natera by 4.5% during the third quarter. Yousif Capital Management LLC now owns 1,682 shares of the medical research company’s stock worth $271,000 after buying an additional 72 shares during the period. Wedmont Private Capital lifted its stake in shares of Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock worth $256,000 after buying an additional 74 shares during the period. Finally, Gries Financial LLC lifted its stake in shares of Natera by 4.0% during the third quarter. Gries Financial LLC now owns 1,904 shares of the medical research company’s stock worth $306,000 after buying an additional 74 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NTRA shares. Stephens restated an “overweight” rating and issued a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Monday. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price objective on the stock in a research note on Monday, July 28th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $196.81.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.